KAZIA THERAPEUTICS LIMITED
Who is KAZIA THERAPEUTICS LIMITED?
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development company. Our lead program is paxalisib, which is being developed to treat glioblastoma (GBM), the most common and aggressive form of primary brain cancer in adults. There are few treatment options for sufferers of GBM...See more
Industry & Specialities
Others
Countries of Operation
Australia
Headquarters:
Australia
Company Type:
MNC / Large Enterprise
Company size:
1-10 Employees
Year Founded:
1994 (32 years)
Address:
300 BARANGAROO AVE; L24; BARANGAROO, NEW SOUTH WALES 2000, AU
Employees by Department
- The Rest (6)
- Total (6)
Key Decision Makers
Chinar Patel
Quality Assurance Lead
David Cain
Craig Kearney
General Manager
Ebru Davidson
Non Executive Director
Insight
Signals
* This information is provided to the best of our research ability and we make no warranties for any inaccuracies or omissions.
Employees by Seniority
C-level
0employees
Senior
0employees
Non-managers
1employees
Financials
LOW
spending power
Funding Status
Publicly listed on stock exchange
Associated Legal Entities
0 entities
Discover More Companies
Lookalike companies
Featured Lists
- SMEs in Singapore
- MNCs / Large Enterprises in Singapore
Frequently Asked Questions (FAQ)
- How long has KAZIA THERAPEUTICS LIMITED been operating for?
- What is the funding status of KAZIA THERAPEUTICS LIMITED?
- Where is KAZIA THERAPEUTICS LIMITED's headquarter?
- What KAZIA THERAPEUTICS LIMITED's spending power?
- Does KAZIA THERAPEUTICS LIMITED have a presence in the domain it operates in?